TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor
2017年8月11日 更新者:BGI, China
Study of DC Vaccine Loaded Tumor Specific Antigen in Treating Patients With Gastrointestinal Solid Tumor
The goal of this study is to learn about the safety and tolerance of autologous TSA-DC cell and evaluate the efficacy and feasibility of the cell therapy compared to the patients' past standard regimen.
20 gastrointestinal solid tumors subjects failed from at least one systemic therapy will be enrolled into the trial and receive a succession of treatment of TSA-DC vaccine.
研究概览
地位
未知
详细说明
20 gastrointestinal solid tumor subjects failed from at least one systemic therapy will be enrolled into the trial .Subjects will be given subcutaneous injection of 5.0x10^6-1.0x10^7
TSA-DC on week 1, 3, 5, 11,17,23,35,47.
Before the first cell infusion, the subjects should undergo a non-myeloablative chemotherapy regimen of Cyclophosphamide 300mg/m2 iv.
Radiologic tumor assessment will be repeated every 8 weeks during treatment, until time of progression.
Treatment will continue until disease progression, intolerance of toxic , withdrawal from the study, study completion, or study termination.
研究类型
介入性
注册 (预期的)
20
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 75年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Be ≥18 and ≤75,no gender based;
- Expression of HLA-A0201/1101/2402;
- Histopathologic documentation of gastrointestinal solid tumors(stomach cancer or colorectal cancer ) concurrent with the diagnosis of metastatic disease, and the tumor is Measurable;
- Patients must have adequate tissue (fresh or paraffin block) for DNA extraction, which is used for gene sequencing, and prognoses the tumor specific antigen in turn,can predict to have new tumor antigens with high affinity for MHC molecules;
- Failure in conventional treatment, or though benefit from chemotherapy the patient can't tolerant subjectively;
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 and an anticipate life expectancy of at least three months,be cooperate to adverse reactions monitoring and therapeutic evaluation of the treatment;
- Participants of child-bearing potential must agree to use adequate contraceptive methods up to 12 months after the pretreatment;
- Serology:Seronegative for HIV antibody,seronegative for hepatitis C antibody. Hematology:Absolute neutrophil count ≥ 1000/mm(3) without the support of filgrastim ,WBC ≥ 3000/mm(3),lymphocyte count ≥ 800/mm(3),Platelet count ≥ 100,000/mm(3),Hemoglobin ≥ 9.0 g/dl Chemistry:Serum ALT/AST ≤ 2.5 times the upper limit of normal,Serum Creatinine ≤1.6 mg/dl,Total bilirubin < 1.5 mg/dl, except in patients with Gilbert s Syndrome who must have a total bilirubin < 3.0 mg/dl;
- Patients or their legal representatives are willing and able to understand and written informed consent form for the trial;
Exclusion Criteria:
- Is pregnant or breastfeeding,or expecting to conceive;
- Have a history of severe immediate hypersensitivity reaction to any of the agents used in this study.
- Suffered grade 3-4 major organ immune-related adverse events after anti-PD1/PDL1 antibody treatment.
- Once received allogeneic organ transplantation (including bone marrow transplantation and peripheral stem cell transplantation, except for corneal transplantation);
- Have clinical symptoms of central nervous system metastases;
- Have used a large number of glucocorticoids or other immunosuppressive agents within 4 weeks;
- Have any active autoimmune disease ;
- Be in active infection or undergo an unknown cause fever> 38.5 ℃ during screening or before the first administration(except tumor fever which evaluated by the researchers have no effect to enrollment );
- Received chemotherapy or small molecule targeted drug therapy in 4 weeks prior to chemotherapy pretreatment;
- Received any antibody drug therapy (including PD-1 and CTLA-4) within 6 weeks before the treatment period;
- Severe liver and kidney dysfunction or uncontrollable diabetes, hypertension and other chronic systemic diseases; severe coagulation disorders, mental illness, cardiopulmonary disease,hydrothorax or ascites;
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Experimental
Drug:Cyclophosphamide Biological/Vaccine:Tumor Specific Antigen-loaded Dendritic Cells |
Subjects will be given subcutaneous injection of 5.0x10^6-1.0x10^7
TSA-DC on week 1,3,5,11,17,23,35,47.
其他名称:
300 mg/m2 by vein before the first cell infusion.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
safety endpoint
大体时间:one year
|
All the local or systemic reactions, adverse events and serious adverse events that occurred between the first and the second TSA-DC administration.
|
one year
|
Overall Response Rate
大体时间:one year
|
Percentage of cases whose tumor shrinks to a certain extent and remains for a certain period of time.
|
one year
|
Proportion of the number of cases that has produced tumor-specific antigen-specific T cells in peripheral blood.
大体时间:one year
|
one year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Secondary safety endpoint
大体时间:one year
|
All local or systemic reactions, adverse events and serious adverse events that occurred from entering the trial until 30 days after the last treatment;
|
one year
|
Six month DCR(CRR+PRR+SDR)
大体时间:6 month
|
Percentage of cases with no progression (CR + PR + SD) in 6 months after initiation of treatment;
|
6 month
|
Duration of Response(DOR)
大体时间:one year
|
The time from the first tumor evaluation of remission(CR + PR ) till the first assessment of PD or the end the study.
|
one year
|
Progression-free survival(PFS)
大体时间:one year
|
The time from entering the trial till the subject has been diagnosed with progression of disease or died.
|
one year
|
rate of 12-month survival
大体时间:one year
|
Percentage of cases with 12 months survival after initiation of treatment in all the subjects;
|
one year
|
Quality score of life improvement
大体时间:one year
|
Evaluated by the questionnaire of life improvement quality collected from the screening to treatment periods.
|
one year
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, Linette GP. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015 May 15;348(6236):803-8. doi: 10.1126/science.aaa3828. Epub 2015 Apr 2.
- Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.
- Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014 May 1;20(9):2433-44. doi: 10.1158/1078-0432.CCR-13-2617. Epub 2014 Feb 28.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (预期的)
2017年12月1日
初级完成 (预期的)
2018年12月1日
研究完成 (预期的)
2019年6月1日
研究注册日期
首次提交
2017年6月11日
首先提交符合 QC 标准的
2017年6月12日
首次发布 (实际的)
2017年6月14日
研究记录更新
最后更新发布 (实际的)
2017年8月14日
上次提交的符合 QC 标准的更新
2017年8月11日
最后验证
2017年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.